Publications
565 results found
Grover V, Pantelidis P, Soni N, et al., 2014, A biomarker panel (Bioscore) incorporating monocytic surface and soluble TREM-1 has high discriminative value for ventilator-associated pneumonia: a prospective observational study, PLOS One, Vol: 9, ISSN: 1932-6203
Wells AU, 2014, Interstitial lung disease in systemic sclerosis, PRESSE MEDICALE, Vol: 43, Pages: E329-E343, ISSN: 0755-4982
- Author Web Link
- Cite
- Citations: 36
Arnold AD, Kouranos V, Wechalekar K, et al., 2014, Immunosuppressive therapy and upgrade of conventional pacemaker to CRT-D for dilated cardiomyopathy due to cardiac sarcoidosis, with discordance of disease activity between PET-CT and CMR, Annual Meeting of the European-Society-of-Cardiology (ESC), Publisher: OXFORD UNIV PRESS, Pages: 1205-1205, ISSN: 0195-668X
Flaherty KR, Fell C, Aubry M-C, et al., 2014, Smoking-related idiopathic interstitial pneumonia, EUROPEAN RESPIRATORY JOURNAL, Vol: 44, Pages: 594-602, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 23
Wells AU, Kokosi M, Karagiannis K, 2014, Treatment strategies for idiopathic interstitial pneumonias, CURRENT OPINION IN PULMONARY MEDICINE, Vol: 20, Pages: 442-448, ISSN: 1070-5287
- Author Web Link
- Cite
- Citations: 15
Lunt A, Desai SR, Wells AU, et al., 2014, Pulmonary function, CT and echocardiographic abnormalities in sickle cell disease, THORAX, Vol: 69, Pages: 746-751, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 31
Corte TJ, Keir GJ, Dimopoulos K, et al., 2014, Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia, American Journal of Respiratory and Critical Care Medicine, Vol: 190, Pages: 208-217, ISSN: 1073-449X
Rationale: Pulmonary hypertension (PH) associated with fibrotic idiopathic interstitial pneumonia (IIP; idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia) confers important additional morbidity and mortality.Objectives: To evaluate the safety and clinical efficacy of the dual endothelin-1 receptor antagonist bosentan in this patient group.Methods: In a randomized, double-blind, placebo-controlled study, 60 patients with fibrotic IIP and right heart catheter confirmed PH were randomized 2:1 to bosentan (n = 40) or placebo (n = 20). The primary study endpoint was a fall from baseline pulmonary vascular resistance index (PVRi) of 20% or more over 16 weeks.Measurements and Main Results: Sixty patients (42 men; mean age, 66.6 ± 9.2 yr), with a mean pulmonary artery pressure of 36.0 (± 8.9) mm Hg, PVRi 13.0 (± 6.7) Wood Units/m2 and reduced cardiac index of 2.21 (± 0.5) L/min/m2 were recruited to the study. Accounting for deaths and withdrawals, paired right heart catheter data were available for analysis in 39 patients (bosentan = 25, placebo = 14). No difference in the primary outcome was detected, with seven (28.0%) patients receiving bosentan, and four (28.6%) receiving placebo achieving a reduction in PVRi of greater than or equal to 20% (P = 0.97) at 16 weeks. There was no change in functional capacity or symptoms between the two groups at 16 weeks, nor any difference in rates of serious adverse events or deaths (three deaths in each group).Conclusions: This study shows no difference in invasive pulmonary hemodynamics, functional capacity, or symptoms between the bosentan and placebo groups over 16 weeks. Our data do not support the use of the dual endothelin-1 receptor antagonist, bosentan, in patients with PH and fibrotic IIP.
Zoumot Z, Boutou AK, Gill SS, et al., 2014, Mycobacterium avium complex infection in non-cystic fibrosis bronchiectasis, RESPIROLOGY, Vol: 19, Pages: 714-722, ISSN: 1323-7799
- Author Web Link
- Cite
- Citations: 51
Desai SR, Edey AJ, Hansell DM, et al., 2014, Morphologic Predictors of a Microbiological Yield in Patients With a Tree-in-Bud Pattern on Computed Tomography, JOURNAL OF THORACIC IMAGING, Vol: 29, Pages: 240-245, ISSN: 0883-5993
- Author Web Link
- Cite
- Citations: 4
McBrien C, Penketh A, Johnson H, et al., 2014, Recurrent pneumothoraces in a 17-year-old man with mixed connective tissue disease, THORAX, Vol: 69, Pages: 685-686, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 2
Nihtyanova SI, Schreiber BE, Ong VH, et al., 2014, Prediction of Pulmonary Complications and Long-Term Survival in Systemic Sclerosis, ARTHRITIS & RHEUMATOLOGY, Vol: 66, Pages: 1625-1635, ISSN: 2326-5191
- Author Web Link
- Cite
- Citations: 309
Kouranos V, Tzelepis GE, Rapti A, et al., 2014, Diagnosis of cardiac sarcoidosis: a crossectional study in 327 consecutive patients, EUROPEAN JOURNAL OF HEART FAILURE, Vol: 16, Pages: 311-311, ISSN: 1388-9842
Wells A, 2014, LUNG DISEASE, Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology, Publisher: OXFORD UNIV PRESS, Pages: 9-10, ISSN: 1462-0324
Keir GJ, Maher TM, Ming D, et al., 2014, Rituximab in severe, treatment-refractory interstitial lung disease, RESPIROLOGY, Vol: 19, Pages: 353-359, ISSN: 1323-7799
- Author Web Link
- Cite
- Citations: 176
Wells AU, Margaritopoulos GA, Antoniou KM, et al., 2014, Interstitial Lung Disease in Systemic Sclerosis, SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 35, Pages: 213-221, ISSN: 1069-3424
- Author Web Link
- Cite
- Citations: 39
Raghu G, Lynch D, Godwin JD, et al., 2014, Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial, LANCET RESPIRATORY MEDICINE, Vol: 2, Pages: 277-284, ISSN: 2213-2600
- Author Web Link
- Cite
- Citations: 135
Keir G, Garske L, Maher T, et al., 2014, RITUXIMAB IN SEVERE, TREATMENT REFRACTORY CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASE, RESPIROLOGY, Vol: 19, Pages: 18-18, ISSN: 1323-7799
- Author Web Link
- Cite
- Citations: 2
Spagnolo P, Sverzellati N, Wells AU, et al., 2014, Imaging aspects of the diagnosis of sarcoidosis, EUROPEAN RADIOLOGY, Vol: 24, Pages: 807-816, ISSN: 0938-7994
- Author Web Link
- Cite
- Citations: 31
Wells AU, Antoniou KM, 2014, The Prognostic Value of the GAP Model In Chronic Interstitial Lung Disease The Quest for a Staging System, CHEST, Vol: 145, Pages: 672-674, ISSN: 0012-3692
- Author Web Link
- Cite
- Citations: 7
Schmidt SL, Tayob N, Han MK, et al., 2014, Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function, CHEST, Vol: 145, Pages: 579-585, ISSN: 0012-3692
- Author Web Link
- Cite
- Citations: 90
Keir GJ, Garfield B, Hansell DM, et al., 2014, Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis, THORAX, Vol: 69, Pages: 287-U93, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 24
Walsh SLF, Sverzellati N, Devaraj A, et al., 2014, Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants, THORAX, Vol: 69, Pages: 216-222, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 145
Walsh SLF, Wells AU, Sverzellati N, et al., 2014, An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study, The Lancet Respiratory Medicine, Vol: 2, Pages: 123-130, ISSN: 2213-2600
BackgroundMortality in pulmonary sarcoidosis is highly variable and a reliable prognostic algorithm for disease staging and for guiding management decisions is needed. The objective of this study is to derive and test a staging system for determining prognosis in pulmonary sarcoidosis.MethodsWe identified the prognostic value of high-resolution computed tomography (HRCT) patterns and pulmonary function tests, including the composite physiological index (CPI) in patients with pulmonary sarcoidosis. We integrated prognostic physiological and HRCT variables to form a clinical staging algorithm predictive of mortality in a test cohort. The staging system was externally validated in a separate cohort by the same methods of discrimination used in the primary analysis and tested for clinical applicability by four test observers.FindingsThe test cohort included 251 patients with pulmonary sarcoidosis in the study referred to the Sarcoidosis clinic at the Royal Brompton Hospital, UK, between Jan 1, 2000, and June 30, 2010. The CPI was the strongest predictor of mortality (HR 1·04, 95% CI 1·02–1·06, p<0·0001) in the test cohort. An optimal CPI threshold of 40 units was identified (HR 4·24, 2·84–6·33, p<0·0001). The CPI40, main pulmonary artery diameter to ascending aorta diameter ratio (MPAD/AAD), and an extent of fibrosis threshold of 20% were combined to form a staging algorithm. When assessed in the validation cohort (n=252), this staging system was strikingly more predictive of mortality than any individual variable alone (HR 5·89, 2·68–10·08, p<0·0001). The staging system was successfully applied to the test and validation cohorts combined, by two radiologists and two physicians.InterpretationA clear prognostic separation of patients with pulmonary sarcoidosis is provided by a simple staging system integrating the CPI and two HRCT variables.FundingNational Insti
van der Plas MN, van Kan C, Blumenthal J, et al., 2014, Pulmonary vascular limitation to exercise and survival in idiopathic pulmonary fibrosis, RESPIROLOGY, Vol: 19, Pages: 269-275, ISSN: 1323-7799
- Author Web Link
- Cite
- Citations: 23
Zappala CJ, Desai SR, Copley SJ, et al., 2014, Accuracy of Individual Variables in the Monitoring of Long-term Change in Pulmonary Sarcoidosis as Judged by Serial High-Resolution CT Scan Data, CHEST, Vol: 145, Pages: 101-107, ISSN: 0012-3692
Antoniou KM, Symvoulakis EK, Margaritopoulos GA, et al., 2014, Early diagnosis of IPF: time for a primary-care case-finding initiative?, LANCET RESPIRATORY MEDICINE, Vol: 2, Pages: E1-E1, ISSN: 2213-2600
- Author Web Link
- Cite
- Citations: 16
Mendoza L, Gogali A, Shrikrishna D, et al., 2014, Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia, RESPIROLOGY, Vol: 19, Pages: 138-143, ISSN: 1323-7799
- Author Web Link
- Cite
- Citations: 38
Tsitoura E, Wells AU, Karagiannis K, et al., 2014, Decreased MicroRNA29a expression in Idiopathic Pulmonary Fibrosis (IPF) is associated with Collagen type, 1a1 expression and eosinophilia in Bronchoalveolar Lavage Fluid (BALF), INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, Vol: 34, Pages: S105-S105, ISSN: 1107-3756
Judson MA, Costabel U, Drent M, et al., 2014, THE WASOG SARCOIDOSIS ORGAN ASSESSMENT INSTRUMENT: AN UPDATE OF A PREVIOUS CLINICAL TOOL, SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, Vol: 31, Pages: 19-27, ISSN: 1124-0490
- Author Web Link
- Cite
- Citations: 325
Keir GJ, Walsh SLF, Gatzoulis MA, et al., 2014, TREATMENT OF SARCOIDOSIS-ASSOCIATED PULMONARY HYPERTENSION: A SINGLE CENTRE RETROSPECTIVE EXPERIENCE USING TARGETED THERAPIES, SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, Vol: 31, Pages: 82-90, ISSN: 1124-0490
- Author Web Link
- Cite
- Citations: 35
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.